Metrics as of 10/15/2026, 05:43 PM (Berlin time), refresh in progress.
Inhibrx Biosciences Stock
Inhibrx Biosciences Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark Lappe
- Employees
- 110
- Market cap
- $1.3 B
- IPO
- 29/05/2024
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize…
Inhibrx Biosciences stock: price history
1D
+5.3%
1W
-3.3%
1M
-15.0%
6M
+8.0%
YTD
+13.6%
1Y
+149.7%
2Y
+470.1%
5Y
+126.0%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~41% stronger price swings than usual
Inhibrx Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 07/08/2026.
Ask the agents about Inhibrx Biosciences
Analyst assessment of Inhibrx Biosciences
PRICE TARGET LOW
US$245.00
CONSENSUS
US$285.00
MEDIAN
US$285.00
PRICE TARGET HIGH
US$325.00
0
STRONG BUY
3
BUY
2
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 22/08/2025
Inhibrx Biosciences stock metrics
P/E
-10.08
P/B
-26.48
EV/EBITDA
-9.88
RETURN ON EQUITY
69.2%
NET MARGIN
0.0%
DEBT/EQUITY
-0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.5%
FLOAT SHARES
10,967,159
AVG. DAILY VOLUME (30D)
302,731
Insider transactions (SEC)
Lappe Mark
Lappe Mark
Lappe Mark
Lappe Mark
Lappe Mark
Attention
Price since yesterday: +5.3%
Search (Google Trends)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Inhibrx Biosciences stock
What does Inhibrx Biosciences do?
Inhibrx Biosciences Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark Lappe, the company employs around 110 people.
The IPO was on 29/05/2024; the stock trades on NASDAQ under the ticker INBX.
What do analysts say about Inhibrx Biosciences stock?
5 analysts rate the stock, the consensus is Buy (as of 22/08/2025).
The average price target is US$285.00, ranging from US$245.00 to US$325.00, with a median of US$285.00.
This is an external assessment, not a statement by Market Jury.
When does Inhibrx Biosciences report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 41% stronger than usual.
Does Inhibrx Biosciences pay a dividend?
Yes. The last dividend was US$0.85 per share, ex-date 30/05/2024, paid on 20/06/2024.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Inhibrx Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Inhibrx Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Inhibrx Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.